Docetaxel and ovarian cancer;Docetaxel et cancer de l'ovaire

Bulletin du Cancer

Volumn 91, Issue 2, 2004, Pages 159-165

  Ray Coquard, Isabelle ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

Chemotherapy; Docetaxel; Ovarian neoplasm; Toxicity

Indexed keywords

CARBOPLATIN; DOCETAXEL; PACLITAXEL; PLATINUM DERIVATIVE;

ADVANCED CANCER; ALLERGY; ALOPECIA; ANEMIA; ASTHENIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; DRUG SAFETY; EVALUATION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PERCEPTION DEAFNESS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRODUCT RECOVERY; QUALITY OF LIFE; REVIEW; SEPSIS; SIDE EFFECT; SURVIVAL; THROMBOCYTOPENIA; TIME; URINE RETENTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; TAXOIDS;

EID: 1842453225     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Colonna M, Hedelin G, Esteve J, Grosclaude P, Launoy G, Buemi A, et al. National cancer prevalence estimation in France. Int J Cancer 2000 ; 87 : 301-4.
2. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2001 ; 51 : 15-36.
3. Hall KL, Dewar MA, Perchalski J. Screening for gynecologic cancer : vulvar, vaginal, endometrial, and ovarian neoplasms. Prim Care 1992 ; 19 : 607-20.
4. Lynch HT, Snyder C, Durham C, Watson P, Lerman C, Lemon SJ. Hereditary ovarian cancer : genetic counseling implications. Cancer Res 1997 ; 38 : 652-3 (abstr.).
5. Levin L, Lund B, Heintz AP. Advanced ovarian cancer : an overview of multi-variate analyses of prognostic variables with special reference to the role of cytoreductive surgery. Ann Oncol 1993 ; 4 (suppl. 4) : 23-9.
6. Kerbrat P, Lhomme C, Pervers B, Guastalla JP, Thomas L, Tournemaine N, et al. Ovarian cancer. Br J Camer 2001 ; 84 (suppl. 2) : 18-23.
7. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996 ; 334 : 1-6.
8. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer : three-year results. J Natl Cancer Inst 2000 ; 92 : 699-708.
9. Du BA, Luck HJ, Meier W, Mobus V, Costa S, Richter B, et al. Carboplatin-paclitaxel versus cisplatin-paclitaxel as first-line chemotherapy in advanced ovarian cancer : an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group. Semin Oncol 1997 ; 24 : S15.
10. Neijt JP, du BA. Paclitaxel-carboplatin for the initial treatment of advanced ovarian cancer. Semin Oncol 1999 ; 26 : 78-83.
11. Baergen R, Bundy BN, Clark-Pearson DL, Fowler JM, Hartenbach E, Mannel R, et al. Randomized phase III study of cisplatin (cis)-paclitaxel (pac) versus carboplatin (carbo)-PAC in optimal stage III epithelial ovarian cancer : a Gynecologic Oncology group Trial (GOG 158). J Clin Oncol 1999 ; 18 : 356 (abstr.).
12. Lavelle F, Bissery MMC, Combeau C. Preclinical evalaution of docetaxel (Taxotere). Semin Oncol 1995 ; 22 (suppl. 4) : 3-16.
13. Braakhuis BJ, Hill BT, Dietel M, Kelland LR, Aapro MS, Zoli W, et al. In vitro antiproliferative activity of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin against human tumour and normal bone marrow cells. Anticancer Res 1994 ; 14 : 205-8.
14. Hanauske AR, Degen D, Hilsenbeck SG, Bissery MC, Von Hoff DD. Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 1992 ; 3 : 121-4.
15. Untch M, Untch A, Sevin BU, Angioli R, Perras JP, Koechli O, et al. Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay. Anticancer Drugs 1994 ; 5 : 24-30.
16. Kelland LR, Abel G. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 1992 ; 30 : 444-50.
17. Boven E, Venema-Gaberscek E, Erkelens CA, Bissery MC, Pinedo HM. Antitumor activity of taxotere (RP 56976, NSC 628503), a new taxol analog, in experimental ovarian cancer. Ann Oncol 1993 ; 4 : 321-4.
18. Nicoletti MI, Lucchini V, D'Incalci M, Giavazzi R. Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts. Eur J Cancer 1994 ; 30A : 691-6.
19. Silvestrini R, Zaffaroni N, Orlandi L, Oriana S. In vitro cytotoxic activity of Taxol and Taxotere on primary cultures and established cell lines of human ovarian cancer. Stem Cells 1993 ; 11 : 528-35.
20. Bissett D, Setanoians A, Cassidy J, Graham MA, Chadwick GA, Wilson P, et al. Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 1993 ; 53 : 523-7.
21. Burris H, Irvin R, Kuhn J, Kalter S, Smith L, Shaffer D, et al. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 1993 ; 11 : 950-8.
22. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995 ; 13 : 2643-55.
23. Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M. Phase I and pharmacokinetic study of Taxotere (RP 56976 ; NSC 628503) given as a short intravenous infusion. Cancer Res 1993 ; 53 : 1037-42.
24. Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN. The taxoids : paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 1993 ; 19 : 351-86.
25. Francis P, Schneider J, Hann L, Balmaceda C, Barakat R, Phillips M, et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994 ; 12 : 2301-8.
26. Kavanagh JJ, Kudelka AP, de Leon CG, Tresukosol D, Hord M, Finnegan MB, et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 1996 ; 2 : 837-42.
27. Kaye SB, Piccart M, Aapro M, Kavanagh J. Docetaxel in advanced ovarian cancer : preliminary results from three phase II trials. EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center. Eur J Cancer 1995 ; 31A (suppl. 4) : S14-S17.
28. Piccart MJ, Gore M, ten Bokkel HW, Van Oosterom A, Verweij J, Wanders J, et al. Docetaxel : an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 1995 ; 87 : 676-81.
29. Kaye SB, Piccart M, Aapro M, Francis P, Kavanagh J. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer : an updated overview. Eur J Cancer 1997 ; 33 : 2167-70.
30. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000 ; 18 : 2354-62.
31. Verschraegen CF, Sittisomwong T, Kudelka AP, Guedes E, Steger M, Nelson-Taylor T, et al. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol 2000 ; 18 : 2733-9.
32. Ray-Coquard I, Bachelot T, Guastalla J, Levy E, Tigaud JD, Vincent P, et al. Epirubicin and paclitaxel (epi-tax regimen) for advanced ovarian cancer after failure of platinum-containing regimens. Gynecol Oncol 2003 (in press).
33. Vasey PA, Atkinson R, Coleman R, Crawford M, Cruickshank M, Eggleton P, et al. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer 2001 ; 84 : 170-8.
34. Vasey PA, Paul J, Birt A, Junor EJ, Reed NS, Symonds RP, et al. Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group. J Clin Oncol 1999 ; 17 : 2069-80.
35. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol 2001 ; 19 : 1901-5.
36. Vasey PA, Paul J, Birt A, Junor EJ, Reed NS, Symonds RP, et al. Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group. J Clin Oncol 1999 ; 17 : 2069-80.
37. Kaye SB, Vasey PA. Docetaxel in ovarian cancer : phase III perspectives and future development. Semin Oncol 2002 ; 29 : 22-7.
38. Vasey PA. Preliminary results of the Scotroc trial : a phase III comparison of paclitaxel-carboplatin (PC) and docetaxel-carboplatin (DC) as first line chemotherapy for stage IC-IV epithelial ovarian cancer. J Clin Oncol 2001 ; 20 : 202a (abstr.).
39. Vasey, PA. Survival and long term toxicity results of the Scotroc trial : doceptaxel-carboplatin versus paclitaxel-carboplatin (PC) in epithelial ovarian cancer. J Clin Oncol 2002 ; 21 : 202a (abstr.).
40. Junor EJ, Hole DJ, McNulty L, Mason M, Young J. Specialist gynaecologists and survival outcome in ovarian cancer : a Scottish national study of 1 866 patients. Br J Obstet Gynaecol 1999 ; 106 : 1130-6.